James Matcham

Vice President, Innovative Statistical Consulting

James joined Cytel in 2020 bringing with him a strong track record in the application of modern statistical methods to decision making, including the design, analysis, reporting and interpretation of clinical trials and observational studies, the implementation of ​​outsourced clinical trial services, and statistical contributions to reimbursement dossiers.

James began his career as a Research Fellow at the Applied Statistics Research Unit at the University of Kent, UK. He went on to complete 21 years with Amgen, where he worked on the development and regulatory/reimbursement approval of many of their biotechnology products while representing the company at regulatory submissions in the US and the EU. This was followed by seven years as VP, Early Clinical Biometrics at AstraZeneca where he led the Global Biometrics team specializing in early clinical trial design, decision-making, and analysis.

James has a master’s degree in Statistics from Imperial College London. His interests include adaptive trial design, the application of Bayesian methods, and quantitative decision-making.

James Matcham

Related Articles

Navigating Dose Optimization in Drug Development: Answering Questions about Project Optimus
Blog
September 5, 2024
Navigating Dose Optimization in Drug Development: Answering Questions about Project Optimus
Read More
FDA’s Project Optimus: Redefining Oncology Drug Dosage for Better Patient Outcomes
Blog
July 2, 2024
FDA’s Project Optimus: Redefining Oncology Drug Dosage for Better Patient Outcomes
Read More
Advancing Innovation in Clinical Trial Design
series
webinar
April 8, 2023
Advancing Innovation in Clinical Trial Design
Read More
Co-Clinical 3: Design considerations for early phase clinical trials of immuno-oncology drug
webinar
January 23, 2023
Co-Clinical 3: Design considerations for early phase clinical trials of immuno-oncology drug
Read More
Future Trials for Combination Cancer Therapy
webinar
June 1, 2023
Future Trials for Combination Cancer Therapy
Read More
Balancing priorities in therapeutics development: simulation-guided decision making
webinar
December 21, 2023
Balancing priorities in therapeutics development: simulation-guided decision making
Read More
How to Ensure Your Adaptive Trial Is Appropriate for Regulatory Submission
Blog
October 4, 2023
How to Ensure Your Adaptive Trial Is Appropriate for Regulatory Submission
Read More